Our Story

We founded MedAvante in 2002 to address a crisis in mental health clinical trials.

Pharma was facing unsustainable failure rates testing psychotropic drugs. Because outcomes in these studies are based on subjective assessments which can be influenced by biases and obscured by variability, developers of treatments for central nervous system (CNS) disorders were having increasing difficulty detecting the conclusive signal needed to prove efficacy, even with treatments already known to be effective.

As a result, pressure was mounting to move drug development investment away from mental health in spite of the large and growing unmet medical need. For us, this was personal: we’d seen individuals close to us devastated by the diseases for which new treatments were needed.

Studying this problem for nearly a year, we came to believe that there had to be a better way. We believed drug developers were not well served by conventional wisdom that said failed trials, soaring costs and untenable delays were unavoidable. And we believed those who said we wouldn’t be able to affect trial failure in a material way were overlooking the tremendous potential of combining scientific, clinical and technical skills to forge a new way of understanding the root causes of bias and variability.

The result was Central Ratings, an unconventional solution built on the novel idea of administering clinical outcome assessments remotely. Centralization effectively blinds raters to potentially prejudicial sources of bias and significantly reduces the number of raters needed for a study, improving standardization and minimizing variability.

As Central Ratings gained acceptance and grew into a global solution, in 2009 we developed a second groundbreaking methodology: replacing paper-based rating scales with real-time digital collection and management “in the cloud” of electronic source data – long before anyone ever heard the term “eSource.”

Our scientific, clinical and technical experience came together again in the Virgil eSource platform, which improves signal detection and data quality by providing any rater – from our own MedAvante cohort or at any study site, anywhere in the world – with real-time clinical guidance, auto-calculated scores and prompts for missing data and out-of-range errors. Virgil can improve clinical trials in any therapeutic area where it’s important to find a clear signal of treatment efficacy.

Virgil has been used by MedAvante Central Raters to administer and score hundreds of thousands of assessments globally and our eSource data has been accepted by both the FDA and the EMA in successful regulatory submissions; these are unique credentials that only MedAvante can claim.

We believe that continuing innovation in the collection, management and analysis of clinical trial data holds the key to unlocking new, more effective treatments. We will continue to build on the great strides we’ve made in signal detection, and we remain fully committed to smarter, faster clinical trials in all therapeutic areas that will bring better treatments to the people who need them most.

Our Vision

We strive for smarter,
faster clinical trials.



Paul M Gilbert

Co-Founder & Chief Executive Officer

Paul Gilbert has 30 years of leadership, strategy, and innovation experience at best-practice organizations including Johnson & Johnson, Arm & Hammer, Booz Allen and Gillette. He has successfully scaled up companies in both consumer and business markets with an emphasis on innovating new markets.

One of three co-founders of MedAvante, Mr. Gilbert has led the building of a global team that now delivers signal detection services for clinical trials in more than 40 countries worldwide. His leadership focus has been on mobilizing exceptional talent, capital and resources to pioneer powerful methodological innovations to address the high rate of failed central nervous system (CNS) clinical trials, including remote Central Ratings and electronic source documents (eSource). He also ensures that MedAvante’s culture, organizational design, business model and strategy reinforce service excellence. Mr. Gilbert led MedAvante’s acquisition of $49 million in growth capital, including an initial $14 million round from 82 organizational leaders from Pharma, Wall Street and innovative growth company CEOs who continue to provide expertise and insights.

Prior to MedAvante, Mr. Gilbert was Vice President of Marketing and Strategy for Princeton eCom, which was awarded New Jersey Technology Council’s 2001 Technology Company of the Year, overseeing the development and execution of all marketing and strategy initiatives.

He has served most recently on the boards of Derma Sciences, a publicly traded tissue regeneration company, and the prestigious non-profit International Longevity Centre Global Alliance (acquired by Columbia University). He’s been invited to present on innovation multiple times at Princeton and Wharton and is a strategic advisor to young innovative companies. In 2012, Mr. Gilbert was awarded the Ernst & Young Lifesciences Entrepreneur of the Year.

Mr. Gilbert graduated magna cum laude from Bowdoin College where he was named a James Bowdoin Scholar, and received his MBA from Harvard University.

Amy Ellis

Co-Founder & President

Amy Ellis is a disruptive innovator who has developed her novel ideas into successful products spanning 21+ consumer, business and healthcare categories. She spearheaded the development of MedAvante’s groundbreaking methodological and technological innovations, including the centralization of drug efficacy trial ratings and the Virgil Investigative Study Platform to change the way human drug trials are conducted. Ms. Ellis is an experienced product developer who grounds visionary ideas in concrete evidence and strategy.

Ms. Ellis was responsible for scaling MedAvante’s innovations from product concept to commercial operations. MedAvante, a new-to-world business, focused on bringing better drug treatments to market for Central Nervous System trials in Psychiatry & Neurology. The high rate of failed trials had doubled the cost to market for CNS drugs and had caused the pharmaceutical industry to reallocate their drug development resources to other therapeutic indications despite the significant societal demand and need for mental health solutions for scourges like Depression, Suicide, Alzheimer’s and Schizophrenia diseases.

While her work has turned pioneering ideas into profitable marketplace realities Ms. Ellis is as proud of the development of a unique company culture and mission that seeks to have every employee to feel their contributions are meaningful and essential. Ms. Ellis always works to foster a sense of employee ownership and transparency at MedAvante by informal as well as formal means such as conducting global town hall meetings to update employees on notable developments and ensuring that each individual understands the company’s overall product strategy. In 2013 she was named to the PharmaVOICE 100, which recognizes inspiring industry leaders.

Prior to MedAvante, Ms. Ellis was the Director of Marketing of Personal Care New Products at Church & Dwight. While there she twice successfully introduced two new national Brands leveraging the Company’s equity in the Arm & Hammer Baking Soda Brand. Her Anti-Perspirant/Deodorant Brand in 1994, still in distribution, utilized new encapsulation technologies and Arm & Hammer Dental Care Gum clinically supported oral health claims and introduced premium pricing into the $2.6B US gum category, previously a value-priced category. It won the American Marketing Association’s Edison Award as the “1998 Best New Product of The Year.”

Before Church & Dwight she managed and developed Brand extensions for established brands such as Old Spice, Pine-Sol and Breck and developed over-the-counter brands for Ciba Consumer Pharmaceuticals (now part of Novartis) and American Cyanamid (now part of Pfizer).

Ms. Ellis has a MBA in Finance and Marketing from the University Of Chicago Booth School Of Business, a MLS from the University of Chicago and a BA in Art History from the University of Rochester.

Steven Downing

Chief Financial Officer

Steve Downing has more than 25 years of experience in finance and business.

Before joining MedAvante, Mr. Downing served as Executive Director of Finance for the Client Support Center of Excellence for Covance. In that position, he led the planning and implementation of a finance reorganization process. Mr. Downing also lent support to responsibility, strategy, capital investment, expansion and financial training. In addition, he led a team responsible for the overall financial health of projects, including profitability, revenue recognition, cash flow, invoicing, and financial training for project managers and their teams.

His previous roles at Covance included Global Controller for the Clinical Development Services Business and Senior Financial Analyst for the Corporate office. Before joining Covance, Mr. Downing worked as a Senior Consolidations Analyst with IMO Industries and as an auditor with KPMG Peat Marwick LLP.

Mr. Downing has a BS in Accounting and Finance from Trenton State College, and is a Certified Public Accountant.

Peter Sorantin, PhD

Senior Vice President, Business Development & Communications

Dr. Sorantin has more than 15 years of experience in the biopharma and chemical industries. Before joining MedAvante, Dr. Sorantin worked in business development at SciQuest, establishing the key account program with international pharma companies and leading the company’s expansion into the European market.

Prior to SciQuest, Dr. Sorantin worked in business development at Molecular Simulations/Accelrys, where he expanded the company into formulation-related applications in pharmaceutical development and consumer care. He began his career at Siemens, leading the initiative to deliver new high-performance computational methods in predictive modeling to pharmaceutical companies and research institutions.

Dr. Sorantin holds a PhD in Physical Chemistry from the Vienna University of Technology in Austria, and has written a variety of scientific publications.

Angela Wilmer

Vice President, Regulatory and Quality Assurance

Since joining MedAvante in 2002, Angela Wilmer has developed provider networks and managed both the Rater Operations and Human Resources departments. She executed the company’s first feasibility study using videoconferencing. As Vice President of Regulatory and Quality Assurance since 2008 she has been responsible for evaluating activities of regulatory significance and ensuring that quality standards and regulatory requirements are implemented and maintained throughout the organization while leading audit teams in successful completion of more than 60 customer audits without a single significant finding. Widely recognized for her achievements in organizational leadership, Ms. Wilmer is often sought for advice and collaboration and asked to share her expertise with professionals worldwide through networking and consulting.

Before joining MedAvante, Ms. Wilmer worked for more than 20 years in health care where she developed expertise in regulation interpretation. At Horizon Blue Cross Blue Shield of New Jersey, she successfully developed and managed health care policies and administrative procedures to ensure compliance with regulatory agencies and other standards for a network of over 10,000 providers. She has developed recruitment, contracting, and retention strategies for employees, physicians, and ancillary providers.

Ms. Wilmer has a BS in Management from the University of Phoenix and will obtain a BA in Professional Counseling from Liberty University in 2017.

Christopher Randolph, PhD

Chief Scientific Officer

Dr. Randolph has extensive experience in CNS clinical trials work, as an investigator, consultant and creator and supervisor of rater training programs for a large number of Phase II and Phase III multinational studies in Alzheimer’s disease and other neurodegenerative conditions; schizophrenia; stroke; hepatic encephalopathy; and traumatic brain injury.

He also has a strong background and interest in psychometrics and neurocognitive assessment, having worked for over 20 years as a consultant on test development, including the revisions of the Wechsler intelligence and memory scales. He is the author of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), a brief neurocognitive battery used widely around the world.

Dr. Randolph is Clinical Professor of Neurology and Director of the Neuropsychology service at Loyola University Medical Center and is board-certified in clinical neuropsychology. He has authored more than 90 peer-reviewed articles on a variety of research interests, including Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, traumatic brain injury, sport-related concussion, Tourette’s syndrome, schizophrenia and hepatic encephalopathy.

Dr. Randolph received an undergraduate degree from Vanderbilt University, and MS and PhD degrees from Rutgers University/University of Medicine and Dentistry of New Jersey. He completed an Intramural Training Award fellowship at the Clinical Brain Disorders Branch of the NIMH, and worked as a senior staff fellow in the Experimental Therapeutics Branch of the NINDS.

Michael J. Detke, MD, PhD

Chief Medical Advisor

Dr. Detke is a psychiatrist with more than 20 years of research experience and extensive clinical and drug development expertise. Before joining MedAvante, he served as Executive Director for Neuroscience Medical Research at Lilly Research Laboratories, where he oversaw all CNS assets in early-phase development, including all psychiatric, neurologic and pain indications. Before that, he was Senior Medical Director responsible for Phase III development for Cymbalta (duloxetine HCl) and Phase IV for Prozac (fluoxetine). This role included registration and regulatory commitment trials for Cymbalta, including major depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia and chronic pain, as well as pediatric trials.

Dr. Detke teaches and supervises medical students and residents as Clinical Professor of Psychiatry at Indiana University School of Medicine. He graduated summa cum laude with a BA and MS in psychology at Yale University, and received his MA, MD and PhD degrees at the University of Pennsylvania, where he was awarded NIH and NIMH fellowships. He trained in medicine and psychiatry at Harvard Medical School and at the Mt. Auburn, McLean and Massachusetts General Hospitals, and he completed a fellowship in psychopharmacology at Harvard Medical School and McLean Hospital.

Dr. Detke has published more than 60 manuscripts in peer-reviewed journals since 1989. He serves as a reviewer for numerous such journals, and is a member of selective scientific organizations such as the ACNP, ASCP, ISCTM and SOBP.

Janet B. W. Williams, PhD

Senior Vice President, Global Science

Dr. Williams has more than 30 years of clinical research experience in both industry and academia.

Before coming to MedAvante in 2007, she worked for 32 years in academic settings, including as Professor of Clinical Psychiatric Social Work in the Departments of Psychiatry and Neurology at Columbia University College of Physicians and Surgeons, and as Research Scientist and Deputy Chief of the Biometrics Research Department at the New York State Psychiatric Institute. She is now Professor Emerita at Columbia University.

Dr. Williams is well known in the field for her development of psychiatric classifications and instruments to measure psychopathology.

Dr. Williams has a BS in Biology from Tufts University, an MS in marine biology from the University of Massachusetts–Dartmouth, and an MS and PhD in social welfare from the Columbia University School of Social Work. She is the author of more than 240 scholarly publications and serves on the editorial boards of several psychiatric and social work journals. She has received numerous awards for her achievements and contributions in social work and psychiatry.

Scott A. Reines, MD, PhD

Senior Scientist

Dr. Reines has more than 30 years of experience, including broad experience as a senior executive in pharmaceutical R&D.

Before retiring in 2008, he was Senior Vice President for CNS, Pain, and Translational Medicine at Johnson & Johnson Pharmaceutical R&D. During his five years at J&J, Dr. Reines had responsibility for the approvals of Invega for schizophrenia, Reminyl extended release for Alzheimer’s disease, Risperdal Consta for schizophrenia and bipolar disorder, Risperdal for autism, and Topamax for migraine headache and monotherapy in epilepsy. His research groups also led development programs for the analgesic drug tapentadol, the long-acting antipsychotic agent paliperidone palmitate, and other potential treatments for CNS disorders.

Before J&J, Dr. Reines served as Vice President, Clinical Research at Merck, where he was responsible for the development of numerous medically important drugs including therapies for chemotherapy-induced nausea and vomiting, migraine headache, Parkinson’s disease and glaucoma.

Dr. Reines received a BS magna cum laude in chemistry from Cornell University, a PhD in bio/organic chemistry from Columbia University, and an MD from Albert Einstein College of Medicine. He has published in numerous scientific journals including Science, JAMA, NEJM, and the ACNP journal Neuropsychopharmacology. He recently served as the first industry co-chair of the Neuroscience Steering Committee, Foundation for NIH Biomarkers Consortium, and is a member of the Institute of Medicine Forum on Neuroscience. He previously served for five years as a member of the National Drug Abuse Advisory Council and its Bioethics Task Force.

Kenneth A. Kobak

Senior Scientist

Dr. Kobak is a psychologist with more than 30 years of clinical research experience in both industry and university medical settings. Throughout his career, he has focused on clinical assessment, rater training, rating scale development and clinical trials methodology.

Prior to MedAvante, Dr. Kobak founded the consultancy Research Training Associates, where he developed new methodologies for training and calibrating raters in clinical trials using digital technologies.

At the University of Wisconsin Medical School and Healthcare Technology Systems, Dr. Kobak managed a clinical trials unit and pioneered the use of computer-administered rating scales in clinical trials. He authored computer-administered versions of several clinician-administered rating scales, including depression and anxiety scales that are widely used today, and a computer-administered version of the PRIME-MD, a diagnostic interview that was published in JAMA.

Dr. Kobak received his BA, MSSW, and PhD from the University of Wisconsin-Madison. He is co-author of the Rater Applied Performance Scale (RAPS), which is widely used to evaluate raters’ applied clinical skills in administering symptom rating scales, and is co-author with Dr. Janet Williams of the SIGMA, a structured interview guide for the Montgomery-Asberg Depression Rating Scale. Dr. Kobak received several NIMH grants to develop and study rater training methodology for depression, schizophrenia, and autism. He received a New Investigator Award from NIMH in 1996, and is a core member of the Depression Rating Scale Standardization Team (DRSST).

Jason Brandt

Senior Scientist

Dr. Brandt is a Professor of Psychiatry and Behavioral Sciences, Professor of Neurology and Director of the Division of Medical Psychology at the Johns Hopkins University School of Medicine. He is also Director of the Cortical Function Laboratory at the Johns Hopkins Hospital.

Dr. Brandt’s research focuses on the neuropsychology of memory and other cognitive disorders as they appear in Alzheimer’s disease, Huntington’s disease, and other dementia syndromes. He has also investigated the cognitive changes associated with epilepsy and its treatments, the psychological consequences of genetic testing for neuropsychiatric disorders, and improved methods for neuropsychological assessment. He published more than 300 journal articles and book chapters on these and related topics. Dr. Brandt developed widely used neuropsychological tests including the Hopkins Verbal Learning Test – Revised and the Telephone Interview for Cognitive Status.

Dr. Brandt served as President of both the Society for Clinical Neuropsychology (APA, Division 40) and the International Neuropsychological Society. He was named a “Hero of Medicine” by TIME magazine in 1997 and received the Career Achievement Award from the International Neuropsychological Society in 2015.

Selam Negash

Senior Scientist

Dr. Negash serves as the scientific lead bridging research and operations to ensure MedAvante clinical trial services are implemented successfully from a scientific and service delivery perspective. Prior to joining MedAvante, she was a Research Associate at the Penn Memory Center, a National Institute on Aging-designated Alzheimer’s Disease Center (ADC). Her work has focused on investigating factors associated with successful cognitive aging, including lifestyle factors such as cognitive activity, and on developing interventions that enhance cognitive fitness in older adults. She also studies successful cognitive aging in minority populations, particularly African-Americans. Her other area of work focuses on examining implicit and explicit learning and memory systems in healthy aging and in mild cognitive impairment.

She received her doctoral training in neuroscience from Georgetown University and completed her postdoctoral training in the Alzheimer’s Disease Research Center at Mayo Clinic Rochester, where she also earned the Master of Science degree in the Clinical Research Program.

John M. Kane, MD

Chief Scientific Advisor

Dr. Kane is Senior Vice President for Behavioral Health Services at North Shore-Long Island Jewish Health System in New Hyde Park, New York. He is Chairman of the Department of Psychiatry at The Zucker Hillside Hospital in Glen Oaks, New York. Additionally, he is Professor and Chairman of Psychiatry at The Hofstra North Shore-LIJ School of Medicine. Dr. Kane earned his medical degree from New York University in New York, New York, and completed his internship and residency in Psychiatry at The Zucker Hillside Hospital. He is a Diplomate of the American Board of Psychiatry and Neurology.

Dr. Kane is the recipient of many awards, including the Lieber Prize, The APA’s Kempf Award and Foundations Prize, the New York State Office of Mental Health Lifetime Achievement Award, The Dean Award from the American College of Psychiatrists. He has served as President of the American Society of Clinical Psychopharmacology, the Psychiatry Research Society and the Schizophrenia International Research Society. Dr. Kane has been the principal investigator for research projects focusing on schizophrenia, psychobiolgy and treatment, recovery, and improving quality and cost of care. He is the author of over 400 peer-reviewed papers and serves on the editorial boards of numerous journals.

Scott Cragg

Mr. Cragg is a co-founder and Partner of Trevi Health Capital, a New York-based healthcare-focused investment firm. Mr. Cragg was previously an investment banker at Groton Partners, a merchant banking firm and, prior to that, a member of the Healthcare & Life Sciences Group at Wasserstein Perella and Prudential Vector Healthcare. Mr. Cragg received a B.A., magna cum laude, from the University of St. Thomas. Mr. Cragg currently serves as a director of CareWell Urgent Care, Deep Vein Medical, Manhattan Physicians Laboratories and MedAvante, and previously served as director of AGI Dermatics.

Scott Gottlieb, MD

Dr. Scott Gottlieb joined NEA as a Venture Partner in 2007, specializing in healthcare investments. Scott is a physician and a Resident Fellow at the American Enterprise Institute, where his work is focused on providing insights into the economic, regulatory and technological forces driving the transformation of healthcare. Prior to joining NEA, Scott served as Deputy Commissioner for Medical and Scientific Affairs at the U.S. Food and Drug Administration and as a senior official at the Centers for Medicare and Medicaid Services. He also previously worked as a healthcare analyst for the investment bank Alex Brown & Sons.

Scott is a regular contributor to the Wall Street Journal editorial page and serves as an editorial board member of the journal Value Based Cancer Care and the Food and Drug Law Institute’s Policy Forum. Scott also serves as an advisor to the National Comprehensive Cancer Network and the National Coalition for Cancer Survivorship. Scott is a member of the policy boards to the Leukemia & Lymphoma Society and the Society of Hospitalist Medicine, and he was appointed by the U.S. Senate to serve on the Federal Health Information Technology Policy Committee.

Scott is a director to American Pathology Partners, Medavante, Aptiv Solutions, and a member of GlaxoSmithKline’s Product Investment Board. He was previously a director to Bravo Health and Molecular Insight Pharmaceuticals (MIPI).

Presently a Clinical Assistant Professor at the New York University School of Medicine, Scott completed a residency in internal medicine at the Mount Sinai Hospital in New York and is a graduate of the Mount Sinai School of Medicine and of Wesleyan University, in Middletown, Connecticut, where he studied Economics.

Richard F. Cimino


Until his retirement, Mr. Richard F. Cimino was Executive Vice President and Group President Clinical Development and Commercialization Services at Covance, Inc. Mr. Cimino oversaw global operations in 60+ countries for Clinical Pharmacology, Early Clinical Development, Phase II/IV Clinical Development, Commercialization Services as well as Covance’s Molecule Development Group. He was a member of the company’s Operating Committee, Executive Committee and Benefits Committee. Mr. Cimino also directed corporate strategy and reported directly to the Chairman and Chief Executive Officer.

Mr. Cimino joined Covance in December 2003. Under Mr. Cimino’s leadership, Covance’s Clinical Development Services business grew considerably, increasing in scale, profitability, size, and strategic service capabilities during his tenure. Prior to joining Covance, Mr. Cimino held several senior management positions during his 20-year career at Eastman Kodak. Most notably, he served as General Manager and Corporate Vice President, Americas, Health Imaging Group, where he was instrumental in the digital transformation of Kodak’s second-largest business, now Carestream Health Inc.

Mr. Cimino also served as an independent director for BioClinca Inc. (BIOC) for six years. He holds a Bachelor of Science degree in biology from the State University of New York at Geneseo.

Ray Martin

Ray Martin is the founder of Crescent Hill Partners LLC, an independent and client centric firm located in Saratoga Springs, NY, that provides financial counseling and investment management to successful individuals and families.

For 25 years, Ray has provided financial counseling, guidance and advice to individuals, families and senior executives of Fortune 500 companies. His clients include successful individuals in New York City, partners of large international law firms and individuals who have worked in senior positions at international banking firms and public companies.

Ray’s expertise is individual financial counseling, where he gains a deep understanding of the client’s financial concerns, objectives and present resources. Through the process of ongoing financial counseling, he partners with clients to address strategic financial planning, estate planning, investment allocation and strategy, income tax planning and risk management.

Prior to founding Crescent Hill, Ray started a national investment advisory business that began at State Street in Boston, and as CEO and President grew the firm to over $5 billion under management. Prior to that, he was a partner of The Ayco Co. LLP, a national financial counseling firm that served key executives at major Fortune 500 companies. And prior to that, Ray began his career with his independent financial planning firm. Ray has experience in financial planning, tax, insurance and benefit and compensation plans and has attained several designations in these areas.

Ray also served as a delegate selected by the White House at the Second National Summit on Retirement Savings, held in Washington D.C.

Over the past 20 years, Ray has also appeared regularly as the CBS Personal Finance contributor on The Early Show, CBS’ morning news program, CBS Radio and the CBS Evening News. He also appears on CBS MoneyWatch.com and writes a regular blog on the site.

Ray has also appeared as a commentator on CBS NewsPath, was a “Today’s Money” correspondent for NBC-TV’s morning newscast TODAY, and he has appeared on CNBC, MSNBC and the Oprah Winfrey Show.

Ray is the author of two books; “Your Financial Guide… Advice for Every Stage of Your Life,“ and “The Rookie’s Guide to Money Management.”

Ray serves on the board of the foundation of the Wesley Health Center Inc. which provides living and care services for seniors. Ray also serves as chairman of the board of MedAvante Inc. a private company which helps large pharmaceutical companies improve drug trial testing.

Ray enjoys spending time with his children and the outdoors, skiing, boating and hunting.

Nigel Brown, PhD

Dr. Nigel Brown has more than 25 years experience in the pharmaceutical, biotech, contract research, and medal technology sectors. He is a successful strategist, operator, and dealmaker, and has led healthcare transactions worth a combined $9.3Bn.

Trained as a chemist, Dr. Brown started his career with The Upjohn Company, later moving to SmithKline Beecham Pharmaceuticals, working in the field of drug metabolism and pharmacokinetics, where he is best known for introducing revolutionary LC/MS/MS technology that materially reduced drug development timelines.

After completion of an MBA, Dr. Brown joined Phoenix International Life Sciences, a high-growth contract research organization (CRO), where he served as general manager responsible for operations in drug discovery and preclinical development. Following the acquisition of Phoenix International by MDS Inc., Dr. Brown assumed general management responsibility for MDS’ operations in preclinical drug development, transgenics, molecular biology and CMC (chemistry, manufacturing and controls).

Following a decade in general management, Dr. Brown shifted focus to corporate strategy and deal making. He was appointed to the Executive Committee of MDS Pharma Services, leading strategy, M&A, marketing, and regulatory functions, helping drive MDS into the top-5 global CRO rankings.

In 2006, Dr. Brown joined Covance, the world’s largest publicly traded CRO, as head of strategy and corporate development, and was appointed a member of the Executive Committee. In the decade that followed, Dr. Brown delivered 19 transactions, including the CRO industry’s largest strategic pharma partnership with Sanofi-Aventis, valued at $2.2Bn) and the strategic sale of Covance to LabCorp for $6.2Bn.

Dr. Brown, who holds bachelors and doctoral degrees from the University of Oxford, and was a Postdoctoral Fellow at MIT, is currently CEO of Princeton Healthcare Advisory LLC, a specialist corporate strategy and M&A advisory firm. He is an active board member in the pharmaceutical, healthcare technology, and diagnostic sectors, a fund advisor for a venture capital group, and an advisor to middle market private equity firms.

Michael Ropacki, PhD

Vice President, Research and Development

Dr. Ropacki is an accomplished clinical researcher with experience in all phases of clinical development. In his current role as Vice President, Research and Development, he serves as the therapeutic leader for Psychiatry and new therapeutic areas, and oversees MedAvante’s scientific research including presentations and publications.

Dr. Ropacki worked for Janssen Research & Development (Johnson & Johnson) for 13 years, and last served as a Director, Clinical Research Neuroscience, Research and Development. In this capacity he was the Clinical Leader the Cognitive Health in Aging Registry: Investigational, Observational and Trial studies in dementia research – Prospective Readiness Cohort (CHARIOT-PRO) program, and was responsible for the development and execution of other clinical programs within the neuroscience therapeutic area.

Dr. Ropacki serves as Co-Chair of a Scientific Advisory Group for the Innovative Medicines Initiative-European Prevention of Alzheimer’s Dementia (IMI-EPAD) program, and is a National Institute of Health (NIH) advisor to the National Institute on Aging (NIA), National Institute of Neurologic Disorders and Stroke (NINDS) and Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). He is a member of the Critical Path Institute’s (C-Path) Coalition Against Major Disease (CAMD) digital Drug Development Tool (dDDT) Team. Previously, he was Co-Chair of the CAMD Preclinical Cognitive Outcome Assessment (COA) team working with the Food and Drug Administration’s Drug Development Tool, COA Qualification Program. Dr. Ropacki authored or co-authored of dozens of published manuscripts and abstracts, and was an Assistant Clinical Professor of Neurology at the Loma Linda University School of Medicine.

Dr. Ropacki holds a bachelor degree Summa Cum Laude from University of Arizona, a master degree and doctorate from Texas Tech University, completed his internship/residency at University of Oklahoma Health Sciences Center in Psychiatry, and two post-doctoral fellowships at Brown University School of Medicine and UCLA School of Medicine in Psychiatry.

Sue Vallow, RPh MBA MA

Vice President, Patient eSolutions

Sue Vallow is a patient-reported outcomes (PRO) scientist with more than 20 years of experience developing and implementing patient-focused outcomes strategies and capabilities in numerous therapeutic areas with a specialty in CNS trials. She leads the expansion of MedAvante’s Virgil Investigative Study Platform into trials that rely on PROs as key endpoint measures.

Prior to joining MedAvante, she was Senior Director and Head of Patient Focused Outcomes at GSK, where she built and managed the team responsible for patient outcomes strategies, as well as electronic patient reported outcomes (ePRO) implementation in clinical trials. Prior to GSK, she worked at Janssen in a leading role for PRO implementation in neuroscience.

Active in industry-wide patient-focused initiatives to forward the science of patient input in drug development, she served as co-chair of the ePRO subcommittee of the Critical-Path Institute’s Patient Reported Outcomes Consortium, a member of PhRMA’s PRO working group, and a leader in the TransCelerate Patient Experience & Technology initiative. She is a co-author of more than 20 peer-reviewed papers and more than 70 research posters and presentations.

Ms. Vallow earned a BS degree in pharmacy and MA in economics from Temple University and an MBA Villanova University.

Ian Neilson

Senior Vice President, Global IT

Ian C. Neilson leads MedAvante’s worldwide IT team, including software and platform development and support, network operations and data management. He has more than 30 years of experience in eClinical development, including 19 years as a key senior IT executive at Covance, now a division of LabCorp Holdings.

Prior to joining MedAvante, he was Vice President, Technology and Innovation within the Clinical Development Services division of Covance. Neilson was a member of the Clinical Development executive leadership team, developing the IT roadmap for long range strategic plans, and he oversaw a team of 100 IT professionals responsible for successfully delivering a multi-year, multi-million dollar process and technology transformation program. Neilson previously led IT Architecture and Compliance for Covance with responsibility for establishing and implementing IT standards, security, and quality and compliance processes across the company. His professional accomplishments at Covance included serving as IT leader on the Diamond II eClinical Initiative, deploying key initiatives such as a state-of-the art CTMS, eTMF, SAS Data Analysis and Reporting, Bedside Data Capture, and Drug Safety process optimization.

Mr. Neilson holds a BA from Heriot-Watt University, Edinburgh.

Keya Watkins

Senior Vice President, Global Operations

Keya Watkins is a clinical research executive with 20 years of experience predominately focused on clinical trial operations management and customer success. She leads the operations team delivering MedAvante product and services worldwide.

Previously, she was Senior Vice President, Clinical Services, with the WIRB-Copernicus Group and Senior Vice President, Clinical Operations with ePharmaSolutions. Prior to that she served in executive leadership roles at Omnicare Clinical Research for 10 years where her focus was on operational efficiency and  global harmonization resulting in  a >15% improvement in departmental operating margins.

Ms. Watkins holds a degree in Pharmacy from Temple University.

Scientific Advisory Boards

Recognized experts and key opinion leaders in various fields play a vital role in shaping and refining MedAvante’s solutions. Our Scientific Advisory Boards meet regularly to review research progress and recommend improvements for our methods and procedures.


Twelve board members from leading universities and research institutions provide counsel and guidance to MedAvante on initiatives relating to mood, anxiety, schizophrenia, and other psychiatric disorders.

MedAvante’s Psychiatric Advisory Board is co-chaired by John M. Kane, MD, Chairman of the Department of Psychiatry at the Zucker Hillside Hospital and Professor of Psychiatry, Neurology and Neuroscience at the Albert Einstein College of Medicine, where he is the Dr. E. Richard Feinberg Chair in Schizophrenia Research.



Eight distinguished experts from leading American and European institutions engaged in neurocognition research guide the development of MedAvante’s signal detection solutions in Alzheimer’s disease, Parkinson’s disease and related neurodegenerative disorders.

MedAvante’s US/European Alzheimer’s advisory board is co-chaired by Jeffrey Cummings, MD, the Director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada.


Our second Alzheimer’s advisory board guides the application of MedAvante’s clinical trial solutions in Japan. Eleven top leaders from major Japanese universities and research institutions provide their expertise to enhance MedAvante’s ability to collect high-quality research data with less error and greater signal detection.

MedAvante’s Japanese Alzheimer’s advisory board is co-chaired by Masatoshi Takeda, MD, PhD, Chairman and Professor of Psychiatry at the Osaka University Graduate School of Medicine.

geo-abstract-green copy


MedAvante’s dedicated Principal Investigator advisory board includes twelve research leaders from major investigative sites to ensure that our services are highly attuned to the needs of clinical trial sites and investigators. Input from this advisory board was instrumental in the development of the Virgil Investigative Study Platform.


MedAvante is always seeking talented
people to join our world-class team.

At MedAvante, we look for colleagues who combine talent with a powerful desire to change healthcare for the better and ensure that effective therapies make it to the patients who need them. This is the mission uniting the clinicians, scientists, technologists, and operations experts whose mix of energy, inventiveness, and skill fuels MedAvante’s relentless quest to improve clinical trials.

We welcome new colleagues who share the commitment to innovation that has won us blue-chip private equity backing from Goldman Sachs, Trevi Health, and Essex Woodlands.

Coworkers brainstorming in a start-up office

We look for:

  • A commitment to making a difference
  • A desire to work with and learn from talented colleagues
  • The ability to be both self-motivated and a team player
  • Intellectual curiosity
  • The passion to build technological tools to conduct more efficient and effective clinical trials
  • The desire to question the status quo and learn from mistakes
  • Comfort with thinking logically
  • A drive to improve and achieve
  • People who are compassionate, visionary, articulate, ambitious, fun, precise, sympathetic, driven, curious, energetic, inspiring and trustworthy

Got what it takes?

See jobs

Application Process

Please apply online with your CV and cover letter in English. Candidates for clinical positions may be asked to complete a Clinical Experience Questionnaire. After the CV screening, selected candidates will be contacted in order to schedule phone or Skype interviews.

We value your interest in MedAvante and try to review all submissions in a timely manner. MedAvante strives to continuously improve our application process and candidate experience. Therefore, we welcome your feedback on Glassdoor or by e-mail to hr@medavante.com

Who we are

About Us

MedAvante, founded in 2002, is a leading global clinical data services company. Our offerings include the tablet-based Virgil Investigative Study Platform and scientific risk-reduction services – including Rater Qualification & Training, Central Review and Central Ratings – to support clinical trials of treatments for central nervous system (CNS) and other disorders.

MedAvante is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age or veteran status.

See jobs

Our Locations

The MedAvante corporate headquarters is located in Hamilton NJ, which is easily accessible via NJ Transit and within walking distance to the Hamilton train station.

Our Munich office was established in 2011 and is functioning as a hub office for providing services in Europe and Asia-Pacific. The office is located within the MTZ technology centre.

In addition MedAvante employs remote, home based employees and consultants in Bangladesh, Bulgaria, Canada, Czech Republic, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Japan, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russia, South Korea, Spain, Turkey, United Kingdom, Ukraine and the United States.


What we offer


MedAvante offers a competitive salary & comprehensive benefits package to eligible employees, including (but not limited to):

In the US:

In all other countries:

See jobs

MedAvante’s Timeline


MedAvante breaks new ground with its Central Ratings methodology.


Building on its Central Ratings expertise, MedAvante pioneers eSource.


MedAvante expands to providing service in global trials.

First MedAvante-generated eSource data accepted by FDA as part of a successful drug approval.


FDA issues guidance encouraging the industry adoption of eSource solutions – which MedAvante has already been developing for five years.


MedAvante launches the Virgil Investigative Study Platform.


Milestone: Three and a half million pages of paper captured digitally by Virgil — without losing a single data point. If stacked, the pages would exceed the height of The Empire State Building.


Virgil continues to evolve with regular platform updates driven by site-based research and feedback.

MedAvante provides global services with native-language clinicians in over 40 countries.

We’re committed to providing the tools for smarter, faster clinical trials. With Virgil, the future looks even brighter.

MedAvante Worldwide